Editors have highlighted the following attributes while ensuring the content's credibility:Credit: Annushka Ahuja from PexelsIn children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes, according to a study published in JAMA Pediatrics. Pareeta Kotecha, Pharm.D., from the University of Florida in Gainesville, and colleagues examined the efficacy and safety of GLP-1 RAs in children and adolescents with obesity, prediabetes, or T2D in a systematic review. Data were included from 18 randomized controlled trials, with 1,402 participants (838 GLP-1 RA users and 564 receiving placebo). "This systematic review and meta-analysis provides a comprehensive evaluation of the benefits and risks associated with GLP-1 RAs in the pediatric population, enabling patients, caregivers, and clinicians to make more informed treatment decisions," the authors write. More information: Pareeta Kotecha et al, Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes, JAMA Pediatrics (2025).